Menu
Search
|

Menu

Close
X

Vanda Pharmaceuticals Inc VNDA.OQ (NASDAQ Stock Exchange Global Market)

19.95 USD
+0.20 (+1.01%)
As of 11:39 AM EDT
chart
Previous Close 19.75
Open 19.80
Volume 17,931
3m Avg Volume 154,938
Today’s High 20.08
Today’s Low 19.75
52 Week High 20.35
52 Week Low 11.90
Shares Outstanding (mil) 52.11
Market Capitalization (mil) 1,031.79
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
44
FY17
165
FY16
146
FY15
110
EPS (USD)
FY18
0.064
FY17
-0.349
FY16
-0.417
FY15
-0.942
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
6.02
8.04
Price to Book (MRQ)
vs sector
4.27
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
0.00
17.43
LT Debt to Equity (MRQ)
vs sector
0.00
13.25
Return on Investment (TTM)
vs sector
-2.58
13.23
Return on Equity (TTM)
vs sector
-2.63
15.27

EXECUTIVE LEADERSHIP

H. Thomas Watkins
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Mihael Polymeropoulos
President, Chief Executive Officer, Director, Since 2010
Salary: $618,000.00
Bonus: $1,483,200.00
James Kelly
Chief Financial Officer, Executive Vice President, Treasurer, Since 2017
Salary: $390,000.00
Bonus: $202,800.00
Gian Piero Reverberi
Senior Vice President, Chief Compliance Officer, Since 2016
Salary: $451,536.00
Bonus: $203,191.00
Gunther Birznieks
Senior Vice President - Business Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2200 Pennsylvania Ave NW Ste 300
WASHINGTON   DC   20037-1754

Phone: +1202.7343400

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

SPONSORED STORIES